atai Life Sciences reports positive data from mid-stage depression trial

1 month ago 3
Genetic engineering concept. Medical science. Scientific Laboratory.

metamorworks/iStock via Getty Images

atai Life Sciences (ATAI) reported promising data on Tuesday from the second part of a mid-stage trial of BPL-003, a psychedelic therapy being developed by Beckley Psytech, for treatment-resistant depression.

Beckley Psytech and atai Life Sciences signed an agreement in

Recommended For You

More Trending News

Read Entire Article